



IDIOPATHIC PULMONARY FIBROSIS IPF & FRIENDS

10th-11th June 2021









IDIOPATHIC PULMONARY FIBROSIS IPF & FRIENDS



RATIONALE

The acronym IPF (Idiopathic Pulmonary Fibrosis) corresponds to a clinical-radiological entity with a corresponding anatomical-pathological pattern. This allowed specialists to be able to communicate internationally with some clarity and certainly facilitated the emergence of multicentre clinical trials, with the aim of introducing new drugs into clinical practice.

Research on the pathogenesis and possible treatments of IPF has recently produced important results. The boundaries between IPF and non-IPF are not always clear if the guidelines are followed. The possibility of analyzing lung tissue in an increasing number of cases, thanks to the use of minimally invasive methods (transbronchial biopsy with cryoprobe), the identification of similar pathogenetic phases in apparently different diseases and the demonstration that specific drugs can reduce the functional decline and the risk of mortality linked to the disease itself make the expansion of the "IPF ensemble" possible and desirable.

The recent SARS-CoV-2 pandemic highlighted new perspectives into being regarding the link between infections and possible Pulmonary Fibrosis. This will be a further starting point for research and discussion.

This course will also be an opportunity to take stock of new management models for these diseases.

Venerino Poletti





IDIOPATHIC PULMONARY FIBROSIS IPF & FRIENDS



Katerina Antoniou, Heraklion (GR)

Elisabeth Bendstrup, Aarhus (DK)

Martina Bonifazi, Ancona

Marco Chilosi, Verona

Bruno Crestani, Parigi

Alessandra Dubini, Forlì

Sergio Harari, Milano

Naftali Kaminski, New Haven (USA)

Sara Piciucchi, Forlì

Stefano Pileri. Milano

Venerino Poletti, Forlì; Aarhus (DK)

Silvia Puglisi, Forlì

Claudia Ravaglia, Forlì

Elisabetta Renzoni, London (UK)

Carlo Salvarani, Reggio Emilia

Alfredo Sebastiani, Roma

Paolo Spagnolo, Padova (PD)

Sara Tomassetti, Firenze

Dominique Valeyre, Parigi

Athol Umfrey Wells, London (UK)







10th June 2021

08:45-09:00 Webinar opening

09:00-09:15 Introduction V. Poletti

I SESSION: Interconnections

Chairperson: V. Poletti

09:15-09:45 Vasculitides:

pathogenetic update C. Salvarani

09:45-10:15 Hodgkin Lymphoma.

History of its definition: from

morphology to molecular biology S. Pileri

10:15-10:45 COVID-19 interstitial pneumonia.

Pathogenesis M. Chilosi

10:45-11:00 Break

II SESSION: ILD-phenotypes

Chairperson: E. Bendstrup

11:00-11:30 Progressive fibrosing ILDs:

what the bounderies? A.U. Wells

11:30-12:00 Hypersensitivity pneumonitis:

different subsets C. Ravaglia

12:00-12:30 IPF:different phenotypes N. Kaminski 12:30-13:00 Alveolar proteinosis B. Crestani

13:00-14:30 Break

III SESSION: Just for fun

14:30-15:00 Why I like the "Canto V"

of the "Inferno",

The Divine Comedy by

Dante Alighieri V. Poletti

15:00-16:00 IV SESSION: Multidisciplinary team at work

Chairperson: E. Renzoni


Speakers: A. Dubini, S. Piciucchi, S. Puglisi











11th June 2021

08:15-08:30 Webinar opening

V SESSION: Diagnostic approach:

Chairperson: A. Sebastiani

08:30-08:50 Transbronchial cryobiopsy/BAL V. Poletti

08:50-09:15 Imaging update in ILDs S. Piciucchi

VI SESSION: Treatment update

Chairperson: M. Bonifazi

09:15-09:45 Collagen vascular disorders E. Renzoni

09:45-10:15 Progressive fibrosing ILDs S. Tomassetti

10:15-10:45 IPF S. Harari

10:45-11:00 Break

VII SESSION: The future

Chairperson: D. Valeyre

11:00-11:30 IPF: from pathogenesis to treatment proposals P. Spagnolo

11:30-12:00 Diagnostic approaches

based on molecular biology K. Antoniou

12:00-13:00 Discussion

13:00-13:15 Final remarks V. Poletti









TECHNICAL INFORMATION

Course held as live webinar via multimedia platform.

Please carefully consult the Program and the timetable to be present in the virtual classroom at the set time. At the end of the Course in Synchronous FAD mode the learner will have 72 hours to fill in the evaluation and satisfaction questionnaires, both essential for obtaining ECM credits. The participation of learners is detected by registering access to the platform. For the purposes of certifying the ECM training credits, the actual presence of 90% of the participants is required the overall duration of the training event. For use and access to the course in Synchronous FAD mode they will be a computer (Windows or Mac) with internet connectivity of a standard navigation browser is required (Internet Explorer, Firefox, Chrome, Opera, Safari)

AIPO DICHIARA CHE LE ATTIVITÀ ECM SONO SVOLTE IN MANIERA AUTONOMA ASSUMENDOSI LA RESPONSABILITÀ DEI CONTENUTI FORMATIVI, DELLA QUALITÀ SCIENTIFICA E DELLA CORRETTEZZA ETICA DI DETTE ATTIVITÀ

CHAIR

Venerino Poletti
Department of Respiratory and Thoracic Diseases
AUSL della Romagna - G.B. Morgagni - L. Pierantoni Hospital, Forlì - IT
Department of Respiratory Diseases and Allergy
Aarhus University Hospital, Aarhus - DK

OFFICIAL LANGUAGE

English

The event time is according to



CONTINUING MEDICAL EDUCATION (CME) ACCREDITATION

The Course will be accredited by ITS-AIPO
AIPO 5079 Standard Accredited Provider
(Italian Association of Hospital Pulmonologists)
to provide Continuing Medical Education (CME)
for Italian Physicians.

Educational objective 2: guidelines, procedures and clinical documentation ID Code: 320560

Number of participants: 100 Italian CME Credits: 18 Profession: Physician

Accredited Disciplines: Pulmonology, Pathological Anatomy, Internal Medicine, Radiology



To certificate CME credits, participants must attend 90% of the Scientific Program

SEGRETERIA ORGANIZZATIVA



Via Antonio da Recanate, 2 20124 MILANO Tel. +39 02 36590350 r.a. Fax +39 02 66790405 segreteria@aiporicerche.it www.aiporicerche.it



Dal 2004 al servizio della Pneumologia Italiana aiposegreteria@aiporicerche.it www.aiponet.it

seguici su





With the unrestricted sponsorship of

